CORDANI, NICOLETTA
 Distribuzione geografica
Continente #
NA - Nord America 2022
EU - Europa 823
AS - Asia 165
Continente sconosciuto - Info sul continente non disponibili 4
Totale 3014
Nazione #
US - Stati Uniti d'America 1981
DE - Germania 219
IT - Italia 201
SE - Svezia 157
CN - Cina 112
UA - Ucraina 81
GB - Regno Unito 48
CA - Canada 40
BE - Belgio 22
IE - Irlanda 20
IN - India 18
FI - Finlandia 16
FR - Francia 16
DK - Danimarca 14
VN - Vietnam 14
TR - Turchia 12
NL - Olanda 7
PL - Polonia 5
EU - Europa 4
JP - Giappone 4
RU - Federazione Russa 4
BG - Bulgaria 3
MT - Malta 3
ES - Italia 2
KR - Corea 2
RO - Romania 2
BA - Bosnia-Erzegovina 1
CH - Svizzera 1
GR - Grecia 1
HK - Hong Kong 1
ID - Indonesia 1
PR - Porto Rico 1
SG - Singapore 1
Totale 3014
Città #
Ann Arbor 574
Woodbridge 219
Chandler 203
Frankfurt am Main 190
Fairfield 168
Houston 141
Wilmington 108
Milan 94
Jacksonville 92
Dearborn 69
Seattle 64
Cambridge 62
Ashburn 54
Princeton 38
Nanjing 37
Brussels 22
Dublin 20
Lawrence 17
Lachine 15
Lissone 12
Nanchang 12
Altamura 10
Beijing 9
Boardman 8
Tianjin 8
Andover 7
Hebei 7
Ottawa 7
Rome 7
San Diego 7
Shenyang 7
Toronto 7
Dong Ket 5
Edmonton 5
Falls Church 5
Fremont 5
Hangzhou 5
Lodz 5
Norwalk 5
Auburn Hills 4
Gallarate 4
Genoa 4
Huizen 4
Jiaxing 4
London 4
Montréal 4
Philadelphia 4
Zhengzhou 4
Changchun 3
Changsha 3
Desio 3
Jinan 3
Los Angeles 3
Marano di Napoli 3
Melita 3
Padova 3
Bursa 2
Cinisello Balsamo 2
Daejeon 2
Inzago 2
Kocaeli 2
Lambesc 2
Lanzhou 2
Maarssen 2
Monza 2
Mumbai 2
Plovdiv 2
Pordenone 2
Quart de Poblet 2
Shanghai 2
Southwark 2
Tokyo 2
Athens 1
Catania 1
Central District 1
Centrale 1
Chicago 1
Curcuris 1
Cusano Milanino 1
Dalmine 1
Eden Prairie 1
Haikou 1
Ilidza 1
Kiev 1
Kil 1
Liberty Lake 1
Lockeford 1
Marseille 1
Montreal 1
Mountain View 1
New Delhi 1
Nichelino 1
Ningbo 1
Nürnberg 1
Oakland 1
Oxford 1
Poggio Renatico 1
Quartu Sant'elena 1
Redmond 1
Rho 1
Totale 2450
Nome #
Lorlatinib treatment elicits multiple on- and off-target mechanisms of resistance in ALK-driven cancer 333
OncoScore: A novel, Internet-based tool to assess the oncogenic potential of genes 252
Erratum: OncoScore: a novel, Internet-based tool to assess the oncogenic potential of genes 242
Chronic myeloid leukemia: Second-line drugs of choice 240
A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib 216
Expression of heat shock protein 27 in human renal cell carcinoma 187
Isolation of FAP Cells from Mouse Dystrophic Skeletal Muscle Using Fluorescence Activated Cell Sorting 168
Mutant p53 subverts p63 control over KLF4 expression in keratinocytes 160
Characterization of heat shock protein 27 phosphorylation sites in renal cell carcinoma 143
Malignant fibrous histiocytoma: a proposed cellular origin and identification of its characterizing gene transcripts 128
Cisplatin may be a valid alternative approach in ovarian carcinoma with carboplatin hypersensitivity. Report of three cases 127
Primary cell cultures arising from normal kidney and renal cell carcinoma retain the proteomic profile of corresponding tissues 126
Nitric Oxide Controls Fat Deposition in Dystrophic Skeletal Muscle by Regulating Fibro-Adipogenic Precursor Differentiation 122
Comparative proteomics of membrane microdomains from renal cell carcinoma and adiacent normal kidney 120
The relative endogenous expression levels of the IFNAR2 isoforms influence the cytostatic and pro-apoptotic effect of IFN alpha on pleomorphic sarcoma cells 92
Derangement of endothelial protein C receptor and thrombomodulin expression in the intestinal mucosa of patients with inflammatory bowel diseases 84
EGFR overexpression in malignant pleural mesothelioma - An immunohistochemical and molecular study with clinico-pathological correlations 82
Expression of endothelial protein C receptor and thrombomodulin in the intestinal tissue of patients with inflammatory bowel disease 76
Investigation of the origin of malignant fibrous histiocytoma and identification of specific predictive markers for this tumour 68
Loss of CDKN2B expression as a potential marker of resistance to CDK4/6 inhibitor in Luminal Breast Cancer cells 39
Novel ALK mutations in EML4::ALK+ NSCLC resistant to TKIs identified by liquid biopsy 30
Baseline 18FDG-PET Metabolic Tumour Volume (MTV) as a Potential Predictive Factor of Response to Metronomic Chemotherapy (mCHT) in HR+/HER2- Metastatic Breast Cancer (MBC) Patients (pts). Preliminary Results of the Metro-pet Study 29
Conditioned Medium of Mesenchymal Stromal Cells Loaded with Paclitaxel Is Effective in Preclinical Models of Triple-Negative Breast Cancer (TNBC) 29
Immunomodulatory effects of metronomic vinorelbine (mVRL), with or without metronomic capecitabine (mCAPE), in hormone receptor positive (HR+)/HER2-negative metastatic breast cancer (MBC) patients: final results of the exploratory phase 2 Victor-5 study 19
Metronomic Chemotherapy for Metastatic Breast Cancer Treatment: Clinical and Preclinical Data between Lights and Shadows 17
How to Treat HR+/HER2-Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story 16
Co-targeting triple-negative breast cancer cells and endothelial cells by metronomic chemotherapy inhibits cell regrowth and migration via downregulation of the FAK/VEGFR2/VEGF axis and autophagy/apoptosis activation 12
Metronomic chemotherapy 11
Harnessing DLL3 inhibition: From old promises to new therapeutic horizons 5
Totale 3173
Categoria #
all - tutte 5521
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5521


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/20186 0000 00 00 0006
2018/2019283 5451 629 2916 21355082
2019/2020670 79544953 6275 9049 64414311
2020/2021593 26266368 6261 5841 44553653
2021/2022293 30424832 821 1315 11192133
2022/2023836 482003991 4672 5752 45888117
Totale 3173